Drug Approval | March 31, 2026
ENHERTU approved in China as first HER2-targeted ADC for early breast cancer
The decision is based on the phase 3 DESTINY-Breast11 trial
The decision is based on the phase 3 DESTINY-Breast11 trial
The new assay consolidates screening for four major viral threats into a single workflow
The partnership has already launched with five active development programs, with both organizations jointly managing regulatory strategy and documentation under a structured, milestone-gated framework
Over the past few months, Apollo Hospitals has entered into MoUs with multiple national and international air ambulance service providers
The presentations underscore the company’s deep expertise in dermatology and immunology
The therapy works by targeting interleukin-13, a key driver of inflammation behind eczema symptoms such as itching, skin damage, and infection
High-level results from the Phase III OBERON and TITANIA trials revealed that the first-in-class monoclonal antibody reduced the annual rate of moderate-to-severe COPD exacerbations compared with placebo
The move comes as drug developers face mounting pressure from faster timelines and increasingly complex manufacturing processes
The programme aims to provide critical healthcare services to approximately 4 lakh people in remote and resource-scarce communities
Subscribe To Our Newsletter & Stay Updated
